Yang, Cheng-Ta

Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study

Johnson, M. L., Cho, B. C., Luft, A., Alatorre-Alexander, J., Geater, S. L., Laktionov, K., Kim, S.-W., Ursol, G., Hussein, M., Lim, F. L., et al. (2023) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 463

Sybil: a validated deep learning model to predict future lung cancer risk from a single low-dose chest computed tomography

Mikhael, P. G., Wohlwend, J., Yala, A., Karstens, L., Xiang, J., Takigami, A. K., Bourgouin, P. P., Chan, P., Mrah, S., Amayri, W., et al. (2023) · Journal of Clinical Oncology

AI in cancer detectionLung Cancer Diagnosis and Treatment

Cited by 288

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

Chiu, C.-H., Yang, C.-T., Shih, J.-Y., Huang, M.-S., Su, W.-C., Lai, R.-S., Wang, C.-C., Hsiao, S.-H., Lin, Y.-C., Ho, C.-L., et al. (2015) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 241

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

Yang, J. C.-H., Camidge, D. R., Yang, C.-T., Zhou, J., Guo, R., Chiu, C.-H., Chang, G.-C., Shiah, H.-S., Chen, Y., Wang, C.-C., et al. (2020) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsPharmacogenetics and Drug Metabolism

Cited by 165

Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis

Kuan, F.-C., Kuo, L.-T., Chen, M.-C., Yang, C.-T., Shi, C.-S., Teng, D., & Lee, K.-D. (2015) · British Journal of Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 101

Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Updated Analysis of the Observational Giotag Study

Hochmair, M. J., Morabito, A., Hao, D., Yang, C.-T., Soo, R. A., Yang, J. C.-H., Gucalp, R., Halmos, B., Wang, L., Märten, A., et al. (2019) · Future Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 85

zVAD-fmk prevents cisplatin-induced cleavage of autophagy proteins but impairs autophagic flux and worsens renal function

Herzog, C., Yang, C., Holmes, A., & Kaushal, G. P. (2012) · American Journal of Physiology-Renal Physiology

Autophagy in Disease and TherapyChemotherapy-induced organ toxicity mitigation

Cited by 82

Severe OSA associated with higher risk of mortality in stage III and IV lung cancer

Huang, H.-Y., Lin, S.-W., Chuang, L.-P., Wang, C.-L., Sun, M.-H., Li, H.-Y., Chang, C.-J., Chang, S.-C., Yang, C.-T., & Chen, N.-H. (2020) · Journal of Clinical Sleep Medicine

Obstructive Sleep Apnea ResearchLung Cancer Diagnosis and Treatment

Cited by 54

A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas

Zhou, Y., Li, M., Zhang, B., Yang, C., Wang, Y., Zheng, S., Tang, L., Zhou, C., Qian, G., Huang, Y., et al. (2023) · BMC Medicine

Sarcoma Diagnosis and TreatmentImmunotherapy and Immune Responses

Cited by 22